Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc.
Your view on ADIL
Overview
What the company does, where it operates, and who runs it.
About Adial Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Cary John Claiborne MBA
- Headquarters
- 1180 Seminole Trail, Charlottesville, VA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Cary John Claiborne MBA
- Headquarters
- 1180 Seminole Trail, Charlottesville, VA, US
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.
The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Adial Pharmaceuticals, Inc. from FRC's valuation model, read against the market price. ADIL last traded at $5.05; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Adial Pharmaceuticals, Inc.. Starting points for Adial Pharmaceuticals, Inc.: EPS -$12.51, beta 1.50 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Adial Pharmaceuticals, Inc.. Adial Pharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Adial Pharmaceuticals, Inc.. Trailing twelve-month EPS for Adial Pharmaceuticals, Inc. stands at -$12.51. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$6.00
Median
$8.50
High
$11.00
Average target
Analyst Ratings
- Strong Buy0
- Buy3
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrSep 2026 | Next QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.18 | -$0.19 | -$2.60 | -$0.61 |
| Low estimate | -$0.18 | -$0.37 | -$2.60 | -$1.17 |
| High estimate | -$0.18 | -$0.01 | -$2.60 | -$0.05 |
| No. of analysts | 1 | 2 | 1 | 2 |
| Year-ago EPS | -$2.00 | -$1.80 | -$11.93 | — |
| Growth | +91.3% | +89.4% | +78.2% | — |
Revenue Estimate
| Revenue | Current QtrSep 2026 | Next QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.00 | $0.00 | $46.00M | $4.40M |
| Low estimate | $0.00 | $0.00 | $46.00M | $4.40M |
| High estimate | $0.00 | $0.00 | $46.00M | $4.40M |
| No. of analysts | 0 | 0 | 1 | 1 |
| Year-ago revenue | $0.00 | $0.00 | $0.00 | — |
| Growth | — | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Adial Pharmaceuticals, Inc.. Adial Pharmaceuticals, Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Adial Pharmaceuticals, Inc. valued side by side against its closest peers. Adial Pharmaceuticals, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Adial Pharmaceuticals, Inc., and how their positions are changing. At a $13.3M market value, institutional positions materially move Adial Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Adial Pharmaceuticals, Inc. executives and directors. Shares of Adial Pharmaceuticals, Inc. have traded between $0.22 and $1.30 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Adial Pharmaceuticals, Inc.. Coverage tracks Adial Pharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Adial Pharmaceuticals, Inc.